Vaughan David Investments LLC IL Buys New Holdings in AstraZeneca PLC $AZNCF

Vaughan David Investments LLC IL bought a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 503,517 shares of the company’s stock, valued at approximately $88,367,000. AstraZeneca makes up approximately 1.9% of Vaughan David Investments LLC IL’s investment portfolio, making the stock its 5th biggest position.

A number of other large investors have also modified their holdings of the company. Hughes Financial Services LLC acquired a new position in shares of AstraZeneca in the fourth quarter valued at $34,000. Alteri Wealth LLC acquired a new position in shares of AstraZeneca in the fourth quarter valued at $650,000. Monetary Management Group Inc. acquired a new position in shares of AstraZeneca in the fourth quarter valued at $1,097,000. Parallel Advisors LLC acquired a new position in shares of AstraZeneca in the fourth quarter valued at $2,689,000. Finally, Root Financial Partners LLC acquired a new position in shares of AstraZeneca in the fourth quarter valued at $622,000. 40.87% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

Shares of OTCMKTS AZNCF opened at $187.10 on Friday. The business has a fifty day simple moving average of $187.10 and a 200 day simple moving average of $185.97. AstraZeneca PLC has a one year low of $122.26 and a one year high of $195.00.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.